En kombination af buprenorphin/naloxon blev lanceret på markedet i EU i 2006 som et alternativ til buprenorphin alene og med det formål at nedbringe muligheden for og ønsket om at injicere det.
A buprenorphine/naloxone combination was launched on the EU market in 2006 as an alternative to buprenorphine alone, with the aim of reducing the potential and attractiveness for injecting use.